Molecular Classification
Other (Metabolic Pathway)
Other Names
ALA metabolism, Omega-3 fatty acid biosynthesis, n-3 PUFA biosynthetic pathway
Disease Roles
Cardiovascular disease (protective role via downstream products EPA/DHA)Inflammation (modulation via omega‑3 derivatives)Arthritis (potentially protective)

Alpha-linolenic acid metabolism pathway Overview

The alpha-linolenic acid metabolism pathway encompasses all biochemical reactions converting dietary alpha-linolenic acid—a plant-derived essential omega‑3 fatty acid—into longer-chain polyunsaturated fatty acids such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Humans cannot synthesize ALA de novo and must obtain it from dietary sources like flaxseed oil, chia seeds, hempseed oil, rapeseed oil, soybeans, and leafy greens. Once ingested, ALA undergoes alternating steps of desaturation and elongation primarily in the endoplasmic reticulum before final beta oxidation steps occur in peroxisomes. Key enzymes include delta‑6 desaturase and delta‑5 desaturase. The resulting long-chain n−3 PUFAs play important roles in reducing inflammation and lowering risks associated with chronic diseases such as cardiovascular disease and arthritis[1][2][5]. In summary: The "alpha-linolenic acid metabolism pathway" is not itself a therapeutic target but rather describes an essential lipid metabolic process involving multiple enzymes that could individually be considered drug targets.[1][2]

Mechanism of Action

Not applicable for the entire pathway. Drugs/supplements may act by providing substrates (e.g., ALA oil supplementation) or by modulating the activity of enzymes within the pathway (e.g., inhibition of delta-6 desaturase).

Biological Functions

Fatty acid elongation and desaturation
Lipid metabolism
Synthesis of long-chain polyunsaturated fatty acids (PUFAs)
Regulation of inflammation

Disease Associations

Cardiovascular disease (protective role via downstream products EPA/DHA)
Inflammation (modulation via omega‑3 derivatives)
Arthritis (potentially protective)

Safety Considerations

  • High intake of certain oils rich in ALA can increase risk of oxidation/rancidity if improperly stored
  • Over-supplementation with omega‑3s may have bleeding risk in some populations

Interacting Drugs

Dietary supplements (ALA, EPA, DHA)
Agents modulating pathway enzymes (e.g., delta-6 desaturase inhibitors)

Associated Biomarkers

Biomarker
Blood levels of ALA
Blood levels of EPA
Blood levels of DHA